BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther 2016;33:699-714. [PMID: 27039186 DOI: 10.1007/s12325-016-0324-7] [Cited by in Crossref: 82] [Cited by in F6Publishing: 65] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
2 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, Abecassis M, Riaz A, Lewandowski RJ, Salem R. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2018;29:1502-1510.e1. [DOI: 10.1016/j.jvir.2018.06.027] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
4 Bundy JJ, Hage AN, Chick JFB, Gemmete JJ, Srinivasa RN, Lee E, Johnson E, Hussain J, Cline M, Patel N, Srinivasa RN. Trends in Interventional Radiology Through the Eye of the Journal of Vascular and Interventional Radiology: A 27-Year History. Curr Probl Diagn Radiol 2019;48:353-8. [PMID: 30054029 DOI: 10.1067/j.cpradiol.2018.05.002] [Reference Citation Analysis]
5 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim HC. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017;23:109-14. [PMID: 28494530 DOI: 10.3350/cmh.2017.0004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
7 Akarca US, Akhan O, Bilgiç S, Bozkurt MF, Cantaşdemir M, Çermik TF, Çakaloğlu Y, Er Ö, Ilgıt E, Çapa Kaya G, Küçük NÖ, Numan F, Parıldar M, Türkmen C. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey. Diagn Interv Radiol 2021;27:732-9. [PMID: 34792027 DOI: 10.5152/dir.2021.201089] [Reference Citation Analysis]
8 Wang K, Mamidipalli A, Retson T, Bahrami N, Hasenstab K, Blansit K, Bass E, Delgado T, Cunha G, Middleton MS, Loomba R, Neuschwander-Tetri BA, Sirlin CB, Hsiao A; members of the NASH Clinical Research Network. Automated CT and MRI Liver Segmentation and Biometry Using a Generalized Convolutional Neural Network. Radiol Artif Intell 2019;1:180022. [PMID: 32582883 DOI: 10.1148/ryai.2019180022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
9 Girotra M, Soota K, Dhaliwal AS, Abraham RR, Garcia-Saenz-de-Sicilia M, Tharian B. Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? World J Gastrointest Endosc 2018; 10(2): 56-68 [PMID: 29467916 DOI: 10.4253/wjge.v10.i2.56] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 dʼAbadie P, Borbath I, Goffette P, Amini N, Lhommel R. Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma. Clin Nucl Med 2019;44:70-1. [PMID: 30394928 DOI: 10.1097/RLU.0000000000002369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Wong YH, Tan HY, Kasbollah A, Abdullah BJJ, Yeong CH. Preparation and In Vitro Evaluation of Neutron-Activated, Theranostic Samarium-153-Labeled Microspheres for Transarterial Radioembolization of Hepatocellular Carcinoma and Liver Metastasis. Pharmaceutics 2019;11:E596. [PMID: 31718079 DOI: 10.3390/pharmaceutics11110596] [Reference Citation Analysis]
12 Li R, Li D, Jia G, Li X, Sun G, Zuo C. Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer. Front Oncol 2020;10:551622. [PMID: 33569342 DOI: 10.3389/fonc.2020.551622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
14 Lucà MG, Nani R, Schranz M, De Giorgio M, Iegri C, Agazzi R, Sala F, Virotta G, Sarti D, Conte G, Pinelli D, Nicora C, Colledan M, Sironi S, Fagiuoli S. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncology 2018;14:727-35. [DOI: 10.2217/fon-2017-0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
16 Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J 2016;22:365-72. [PMID: 27870678 DOI: 10.1097/PPO.0000000000000227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Bornemann S, Herzog M, Winter R. Impact of Y 3+ -ions on the structure and phase behavior of phospholipid model membranes. Phys Chem Chem Phys 2019;21:5730-43. [DOI: 10.1039/c8cp07413e] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Curr Oncol Rep 2017;19:40. [PMID: 28421483 DOI: 10.1007/s11912-017-0597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
19 Hatzidakis A, Müller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel) 2022;14:2469. [PMID: 35626073 DOI: 10.3390/cancers14102469] [Reference Citation Analysis]
20 Venkatanarasimha N, Gogna A, Tong KTA, Damodharan K, Chow PKH, Lo RHG, Chandramohan S. Radioembolisation of hepatocellular carcinoma: a primer. Clin Radiol. 2017;72:1002-1013. [PMID: 29032802 DOI: 10.1016/j.crad.2017.07.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
21 Cardarelli-Leite L, Chung J, Klass D, Marquez V, Chou F, Ho S, Walton H, Lim H, Tae Wan Kim P, Hadjivassiliou A, Liu DM. Ablative Transarterial Radioembolization Improves Survival in Patients with HCC and Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol 2020;43:411-22. [PMID: 31909439 DOI: 10.1007/s00270-019-02404-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
22 Aguado A, Dunn SP, Averill LW, Chikwava KR, Gresh R, Rabinowitz D, Katzenstein HM. Successful use of transarterial radioembolization with yttrium-90 (TARE-Y90) in two children with hepatoblastoma. Pediatr Blood Cancer 2020;67:e28421. [PMID: 32603027 DOI: 10.1002/pbc.28421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 d'Abadie P, Walrand S, Hesse M, Annet L, Borbath I, Van den Eynde M, Lhommel R, Jamar F. Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. Nucl Med Commun 2021;42:747-54. [PMID: 33741864 DOI: 10.1097/MNM.0000000000001395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Aguado A, Ristagno R, Towbin AJ, Gupta A, Haberle S, Qi Z, Patel MN, Kukreja KU, Tiao GM, Geller JI. Transarterial radioembolization with yttrium‐90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer 2019;66:e27510. [DOI: 10.1002/pbc.27510] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Mendiratta-lala M, William M, Shampain K, Zhang A, Jo A, Moorman S, Aslam A, Mature K, Davenport M. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiology: Imaging Cancer. 2020;2. [PMID: 33778692 DOI: 10.1148/rycan.2020190024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Murali N, Ludwig JM, Nezami N, Kim HS. Oligometastatic Disease and Interventional Oncology: Rationale and Research Directions. Cancer J 2020;26:166-73. [PMID: 32205542 DOI: 10.1097/PPO.0000000000000442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ali R, Riaz A, Gabr A, Abouchaleh N, Mora R, Al Asadi A, Caicedo JC, Abecassis M, Katariya N, Maddur H, Kulik L, Lewandowski RJ, Salem R. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. Eur J Nucl Med Mol Imaging 2017;44:2195-202. [DOI: 10.1007/s00259-017-3792-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
28 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
29 Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, Lepareur N. Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres. Biomed Res Int 2018;2018:1435302. [PMID: 30687734 DOI: 10.1155/2018/1435302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
30 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
31 Balli HT, Aikimbaev K, Guney IB, Piskin FC, Yagci-Kupeli B, Kupeli S, Kanmaz T. Trans-Arterial Radioembolization with Yttrium-90 of Unresectable and Systemic Chemotherapy Resistant Hepatoblastoma in Three Toddlers. Cardiovasc Intervent Radiol 2022. [PMID: 35034139 DOI: 10.1007/s00270-021-03026-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chaikajornwat J, Tanasoontrarat W, Phathong C, Pinjaroen N, Chaiteerakij R. Clinical outcome of Yttrium-90 selective internal radiation therapy (Y-90 SIRT) in unresectable hepatocellular carcinoma: Experience from a tertiary care center. Liver Research 2021. [DOI: 10.1016/j.livres.2021.07.001] [Reference Citation Analysis]
33 Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, Lai L, Hazirah SN, Lim TKH, Goh BKP, Chung A, Lo RHG, Ng D, Filarca RLF, Albani S, Chow PKH. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut 2019;68:335-46. [PMID: 29440463 DOI: 10.1136/gutjnl-2017-315485] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 24.0] [Reference Citation Analysis]
34 Joo I, Kim HC, Kim GM, Paeng JC. Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol 2018;19:209-22. [PMID: 29520178 DOI: 10.3348/kjr.2018.19.2.209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
35 Ali R, Gabr A, Abouchaleh N, Al Asadi A, Mora RA, Kulik L, Abecassis M, Riaz A, Salem R, Lewandowski RJ. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases. Cardiovasc Intervent Radiol 2018;41:260-9. [DOI: 10.1007/s00270-017-1791-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
36 Ertreo M, Choi H, Field D, Lischalk JW, Cohen E, Lynskey GE, Caridi T, Buckley D, Unger K, Kim AY. Comparison of Cone-Beam Tomography and Cross-Sectional Imaging for Volumetric and Dosimetric Calculations in Resin Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol 2018;41:1857-66. [PMID: 30006891 DOI: 10.1007/s00270-018-2030-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Ghosh A, Zhang J, Akhter NM. Transradial versus transfemoral arterial access in Yttrium-90 microspheres radioembolization for hepatocellular carcinoma. JCIS 2022;12:27. [DOI: 10.25259/jcis_213_2021] [Reference Citation Analysis]
38 Koh S, Maki EJ, Kolbeck KJ, Farsad K. Skin ischemia and ulceration as a complication of inferior phrenic artery embolization for hepatocellular carcinoma. Radiology Case Reports 2018;13:648-51. [DOI: 10.1016/j.radcr.2018.02.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Alem Z, Murray TE, Egri C, Chung J, Liu D, Elsayes KM, Chang SD, Harris A. Treatment response assessment following transarterial radioembolization for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3596-614. [PMID: 33909092 DOI: 10.1007/s00261-021-03095-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Ahmed O. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointest Tumors 2020;7:144-50. [PMID: 33173778 DOI: 10.1159/000508386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Auditore L, Amato E, Boughdad S, Meyer M, Testart N, Cicone F, Beigelman-Aubry C, Prior JO, Schaefer N, Gnesin S. Monte Carlo 90Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol 2020;65:235014. [PMID: 33245055 DOI: 10.1088/1361-6560/abbc80] [Reference Citation Analysis]
42 Miranda VM. Medicinal inorganic chemistry: an updated review on the status of metallodrugs and prominent metallodrug candidates. Reviews in Inorganic Chemistry 2021;0:000010151520200030. [DOI: 10.1515/revic-2020-0030] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Hansen T, Olsen K, White K, Keller J. Retiform Purpura After Transcatheter Arterial Chemoembolization: A Case Report. The American Journal of Dermatopathology 2018;40:e25-7. [DOI: 10.1097/dad.0000000000000950] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
44 Lüdemann W, Kahn J, Pustelnik D, Hardt J, Böning G, Jonczyk M, Amthauer H, Gebauer B, Hamm B, Wieners G. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. Eur Radiol 2022. [PMID: 35230518 DOI: 10.1007/s00330-022-08585-x] [Reference Citation Analysis]
45 Schobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic LJ. Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization. J Nucl Med 2019;60:1066-72. [PMID: 30655331 DOI: 10.2967/jnumed.118.219691] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Ferrucci PF, Cocorocchio E, Bonomo G, Varano GM, Della Vigna P, Orsi F. A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. Cells 2021;10:E70. [PMID: 33466278 DOI: 10.3390/cells10010070] [Reference Citation Analysis]
47 Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S. Proton beam therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17:911-924. [PMID: 28825506 DOI: 10.1080/14737140.2017.1368392] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
48 Cho SM, Chu HH, Kim JW, Kim JH, Gwon DI. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. Life (Basel) 2021;11:358. [PMID: 33919658 DOI: 10.3390/life11040358] [Reference Citation Analysis]
49 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Le Fur M, Fougère O, Lepareur N, Rousseaux O, Tripier R, Beyler M. Tuning the lipophilic nature of pyclen-based 90Y3+ radiopharmaceuticals for β-radiotherapy. Metallomics 2021;13:mfab070. [PMID: 34850060 DOI: 10.1093/mtomcs/mfab070] [Reference Citation Analysis]
51 Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72:626-635. [PMID: 28258743 DOI: 10.1016/j.crad.2017.01.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
52 Tovar-Felice G, García-Gámez A, Benito-Santamaría V, Balaguer-Paniagua D, Villalba-Auñón J, Sampere-Moragues J. Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. Hepat Oncol 2021;8:HEP38. [PMID: 34408848 DOI: 10.2217/hep-2020-0035] [Reference Citation Analysis]
53 Gabr A, Abouchaleh N, Ali R, Vouche M, Atassi R, Memon K, Asadi AA, Baker T, Caicedo JC, Desai K, Fryer J, Hickey R, Abeccassis M, Habib A, Hohlastos E, Ganger D, Kulik L, Lewandowski RJ, Riaz A, Salem R. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology 2017;93:100-6. [DOI: 10.1016/j.ejrad.2017.05.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
54 Zori AG, Ismael MN, Limaye AR, Firpi R, Morelli G, Soldevila-Pico C, Suman A, Vogel JD, Lazarowicz M, Geller BS, Toskich B, Gonzalo DH, Johnson MW, Cabrera R. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation. Am J Clin Oncol 2020;43:325-33. [PMID: 32079854 DOI: 10.1097/COC.0000000000000678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
55 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
56 Koirala N, Das D, Fayazzadeh E, Sen S, McClain A, Puskas JE, Drazba JA, McLennan G. Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma. J Biomed Mater Res A 2019;107:2522-35. [PMID: 31334591 DOI: 10.1002/jbm.a.36758] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
57 Luna Pais H, Alho I, Vendrell I, Mansinho A, Costa L. Radionuclides in oncology clinical practice – review of the literature. Dalton Trans 2017;46:14475-87. [DOI: 10.1039/c7dt01929g] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
58 Semaan S, Makkar J, Lewis S, Chatterji M, Kim E, Taouli B. Imaging of Hepatocellular Carcinoma Response After 90 Y Radioembolization. American Journal of Roentgenology 2017;209:W263-76. [DOI: 10.2214/ajr.17.17993] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
59 Kapoor H, Sanampudi S, Owen J, Raissi D. Lung Metastasis Postradioembolization of Hepatocellular Carcinoma With Tumor in Vein. ACG Case Rep J 2020;7:e00322. [PMID: 32440525 DOI: 10.14309/crj.0000000000000322] [Reference Citation Analysis]
60 Pang F, Li Y, Zhang W, Xia C, He Q, Li Z, Xiao L, Song S, Dong P, Zhou H, Shao T, Cai H, Li L. Biodegradable 131 Iodine-Labeled Microspheres: Potential Transarterial Radioembolization Biomaterial for Primary Hepatocellular Carcinoma Treatment. Adv Healthc Mater 2020;9:e2000028. [PMID: 32431090 DOI: 10.1002/adhm.202000028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
61 Gunduz S, Albadawi H, Oklu R. Robotic Devices for Minimally Invasive Endovascular Interventions: A New Dawn for Interventional Radiology. Advanced Intelligent Systems 2021;3:2000181. [DOI: 10.1002/aisy.202000181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
62 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
63 Zane KE, Nagib PB, Jalil S, Mumtaz K, Makary MS. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma. World J Hepatol 2022; 14(5): 885-895 [DOI: 10.4254/wjh.v14.i5.885] [Reference Citation Analysis]
64 Gabr A, Ali R, Al Asadi A, Mora R, Mouli S, Riaz A, Salem R, Lewandowski RJ. Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. Tech Vasc Interv Radiol. 2019;22:93-99. [PMID: 31079717 DOI: 10.1053/j.tvir.2019.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
65 Commander CW, Mauro DM. Current Approach to Planning Angiography and MAA Administration. Semin Intervent Radiol 2021;38:397-404. [PMID: 34629705 DOI: 10.1055/s-0041-1735616] [Reference Citation Analysis]
66 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]